The Peptide Boom Is Changing Pharmaceutical Distribution
Insulin made peptide medicines part of everyday healthcare long before semaglutide and tirzepatide became familiar names. What the growth of GLP-1-based therapies has changed is the commercial scale of the category, and the attention paid to the infrastructure needed to supply it.
The numbers give some sense of that shift. In its second-quarter 2026 results, Eli Lilly reported worldwide Mounjaro revenue of approximately US$9.9 billion and Zepbound revenue of approximately US$4.9 billion. The company attributed growth in both products to strong demand or volume growth, partly offset by lower realised prices.
Revenue is not a measure of parcels shipped, and two products do not represent the entire peptide market. Nevertheless, their scale makes distribution a substantial operating consideration. A successful medicine needs more than manufacturing capacity. It needs a repeatable way to reach the pharmacies, clinics and patients relying on it.
For temperature-controlled packaging, that creates a more demanding brief: protect the particular formulation, support the intended distribution model and do so consistently as volumes grow.
A broader category than weight management
GLP-1-based medicines are the most visible part of the peptide story, but they are not the whole category. A 2025 review in Peptides reported that more than 40 peptide drugs had been approved for clinical use over the preceding decade, covering metabolic disorders, genetic diseases, acute illnesses and other indications.
That breadth matters commercially. A product supplied to a specialist treatment centre can have a very different distribution model from a medicine dispensed repeatedly through community or home-delivery channels. Both may be peptides, but their shipment sizes, destinations and handling arrangements need separate consideration.
The category also includes different formulations and delivery routes. Treating peptide growth as a single refrigeration opportunity would therefore be misleading. The more useful question is which products are growing, how they are supplied and what conditions each needs along the way.
For manufacturers and logistics providers, demand planning should connect those product details with the actual distribution network. An increase in sales does not translate neatly into a corresponding increase in insulated parcels.
Growth reaches the fulfilment operation
Where refrigerated medicines are supplied through parcel networks, the practical challenge becomes visible at the packing bench.
An order needs the correct product presentation and a suitable shipper. Coolant must be ready when required. Staff need clear instructions, and the carrier service must fit the period of protection the packaging provides. These tasks recur throughout the dispatch day, rather than only when a new medicine launches.
As volumes increase, businesses need to establish whether the process can expand without depending on additional manual intervention. A configuration that is straightforward for an experienced operator may be less reliable when several sites, shifts or temporary staff are involved.
This makes the packing process part of the commercial assessment. How many configurations must staff distinguish? Can the materials be replenished reliably? Does conditioning capacity support the intended dispatch volume? What happens when the usual carrier collection is missed?
The answers determine whether a packaging system can support growth in practice. Thermal performance remains essential, but it must be delivered through a process the fulfilment operation can repeat.
Peptide does not automatically mean refrigerated
The differences between products are already apparent in approved medicines.
Novo Nordisk’s U.S. storage instructions for Rybelsus, an oral semaglutide product, specify room-temperature storage at 20°C to 25°C and protection from moisture in its original bottle. That is a different requirement from the refrigerated storage associated with many injectable presentations.
The distinction is important for businesses assessing the future market. Progress in formulation and delivery can change the protection a product requires. Growth in peptide therapeutics should not be presented as proof that every future medicine in the category will need the same cold chain.
Packaging decisions need to begin with the approved product information and any additional manufacturer requirements. The active ingredient’s name, or its membership of a therapeutic class, is not enough to define the shipping specification.
For a distributor handling several peptide products, this also creates an information-management task. Product records and packing instructions must distinguish the formulation, presentation and destination market. Staff should not have to infer storage requirements from a familiar brand or molecule.
Capacity includes packaging supply
Manufacturing expansion can only support distribution if the materials needed to dispatch the finished product are available.
For a refrigerated parcel programme, that includes insulation, coolant, outer cartons and any required monitoring components. It also includes the equipment, space and time needed to prepare them. A forecast for increased medicine output should therefore be translated into an operating forecast for packaging and fulfilment.
The relevant questions are specific. Which sites will dispatch the product? What proportion of orders will use each shipper size? How much conditioned coolant must be available at the start of a shift? Can an alternative supply location provide the same specification if the primary source is disrupted?
These considerations become particularly important when a business adds fulfilment sites. Buying a similar-looking component locally does not establish that it is interchangeable with the tested material. Substitutions need to be assessed before operational pressure makes them the default.
Supply continuity is consequently part of packaging performance. A system that works well in testing still needs a credible procurement and replenishment plan.
The economics are in the repeated shipment
The commercial effect of packaging becomes clearer when it is considered across routine dispatches.
Excess carton volume can affect freight and storage costs. A complicated assembly process can add labour and create more opportunities for variation. A poorly matched configuration may require orders to be split or repacked. These are costs to measure, rather than assume from the packaging price alone.
The comparison should begin after acceptable product protection has been established. It can then examine materials, conditioning, packing time and freight alongside the effort required to manage exceptions. Estimates of avoided product loss should remain separate unless reliable data supports them.
For peptide manufacturers and distributors, the objective is a system that fits the medicine and the intended service. Sometimes that will require refrigerated packaging; in other cases, the product specification will support a different approach.
The growth of peptide therapeutics creates a substantial distribution opportunity, but it rewards specificity. Businesses need to understand what is being shipped, where it is going and how the process will operate at the intended volume. Packaging earns its place by making that distribution dependable and commercially workable.
Information reviewed on 29 October 2026. Storage requirements must be confirmed for the specific product, presentation and market.

All materials supplied by Thermogard are recyclable, reusable, or biodegradable to promote a circular economy. Follow our guides below for safe and responsible recycling or reuse of your Thermogard packaging materials.
